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The dissociation of 80S ribosomes 
after termination is promoted by trans-
lation initiation factors eIF1, eIF1A, and 
the eIF3 complex (Pisarev et al., 2007). 
In light of this, the second observation 
by Bolger et al. implicating Gle1 in the 
initiation step of translation is particu-
larly exciting. Bolger and colleagues 
link Gle1 with two subunits of the eIF3 
complex: Gle1 has genetic interactions 
with Nip1 (eIF3c) and physically asso-
ciates with Prt1 (eIF3b). Furthermore, 
cells lacking functional Gle1 accumulate 
80S monosomes, indicative of a defect 
in translation initiation. Although cells 
lacking Dbp5 also exhibit accumulation 
of 80S monosomes (Gross et al., 2007), 
there is no evidence yet for a genetic or 
physical interaction of Dbp5 with the 
translation initiation machinery. More-
over, the IP6 pathway was not found to 
be required for initiation, suggesting that 
Gle1/IP6-dependent activation of Dbp5 
is not the mechanism underlying Gle1’s 
role in initiation. Rather, the authors put 
forward the attractive model that Gle1 
could contribute to ribosomal sub-
unit recycling in conjunction with eIF3, 
thereby helping to couple translation 
termination to the next round of initia-
tion. Alternatively, Gle1 might influence 
initiation independently of its role in 
termination. More biochemical experi-
ments will be required to clarify the role 
of Gle1, and potentially Dbp5, in transla-
tion initiation.
The new roles for Gle1 may have impli-
cations for understanding human dis-
eases caused by mutations in human 
GLE1 (hGLE1). A recent study reported 
that heritable mutations in hGLE1 are the 
cause of lethal congenital contracture 
syndrome type 1 (LCCS1), a fetal motor 
neuron disease associated with prena-
tal death. Two related disorders, LCCS2 
and LCCS3, have also been analyzed, 
and those mutations map to factors act-
ing in the phosphatidyl inositol pathway 
(Nousiainen et al., 2008, and references 
therein). The new findings by Bolger et al. 
implicating Gle1 and IP6 in mRNA export 
and translation beg the question of 
whether these syndromes could be due 
to defects in translation or mRNA export. 
Future functional analysis of the inher-
ited mutations in these diseases could 
provide valuable insights into the molec-
ular defects underlying human pathology 
caused by mutations in GLE1.
RefeRences
Alcazar-Roman, A.R., Tran, E.J., Guo, S., and 
Wente, S.R. (2006). Nat. Cell Biol. 8, 711–716.
Bolger, T.A., Folkmann, A.W., Tran, E.J., and 
Wente, S.R. (2008). Cell, this issue.
Cole, C.N., and Scarcelli, J.J. (2006). Curr. Opin. 
Cell Biol. 18, 299–306.
Gross, T., Siepmann, A., Sturm, D., Windgassen, 
M., Scarcelli, J.J., Seedorf, M., Cole, C.N., and 
Krebber, H. (2007). Science 315, 646–649.
Lund, M.K., and Guthrie, C. (2005). Mol. Cell 20, 
645–651.
Nousiainen, H.O., Kestila, M., Pakkasjarvi, N., 
Honkala, H., Kuure, S., Tallila, J., Vuopala, K., Ig-
natius, J., Herva, R., and Peltonen, L. (2008). Nat. 
Genet. 40, 155–157.
Pisarev, A.V., Hellen, C.U., and Pestova, T.V. (2007). 
Cell 131, 286–299.
Tran, E.J., Zhou, Y., Corbett, A.H., and Wente, S.R. 
(2007). Mol. Cell 28, 850–859.
Weirich, C.S., Erzberger, J.P., Flick, J.S., Berger, 
J.M., Thorner, J., and Weis, K. (2006). Nat. Cell 
Biol. 8, 668–676.silencing HIV-1 In Vivo
Frank Kirchhoff1,*
1Institute of Virology, University of Ulm, 89081 Ulm, Germany
*Correspondence: frank.kirchhoff@uniklinik-ulm.de
DOI 10.1016/j.cell.2008.08.004
RNA interference holds great promise for antiviral therapy, but delivering effective quantities of 
small interfering RNAs (siRNAs) into the right target cells in vivo represents a major challenge. 
Kumar et al. (2008) now report a technique to target siRNAs specifically to T cells to suppress viral 
infection in a humanized mouse model of HIV/AIDS.With the discovery that RNA interfer-
ence (RNAi) occurs in mammalian cells 
(Elbashir et al., 2001), it immediately 
became clear that RNAi is not only a 
powerful tool for basic research but 
also may represent a new therapeu-
tic approach against viral infections 
and cancer. Numerous studies have 
established the proof of concept that 
diseases can be targeted by therapeu-566 Cell 134, August 22, 2008 ©2008 Elsevitic RNAi, and several small interfer-
ing RNAs (siRNAs) are currently being 
tested in clinical trials (Grimm and Kay, 
2007). Despite these rapid advances, 
significant hurdles still need to be 
overcome for the widespread thera-
peutic application of siRNAs. Perhaps 
the greatest challenge is the delivery 
of effective quantities of siRNAs into 
the cytoplasm of relevant target cells er Inc.in vivo (Dykxhoorn and Lieberman, 
2006). There are additional challenges 
for using siRNAs in the treatment of 
HIV-1 infection, including validating the 
approach in a relevant animal model 
and preventing the emergence of vari-
ants resistant to treatment because of 
the high sequence diversity of the virus. 
In this issue, Kumar et al. (2008) exploit 
a series of recent technical advances to 
overcome these obstacles. They dem-
onstrate that targeting a combination 
of host and viral proteins with siRNAs 
can efficiently inhibit HIV-1 infection in 
a humanized mouse model.
It has been shown previously that 
antibodies can be used to deliver 
 siRNAs into the cytoplasm of specific 
target cells (Song et al., 2005). This 
approach decreases the amount of 
siRNA that is needed, thereby mini-
mizing the risk of undesired effects 
in bystander cells. In their new work, 
Kumar et al. use a single-chain anti-
body to the CD7 receptor conjugated 
to a nonamer arginine peptide (9R) 
(Figure 1). The CD7-specific antibody is 
well suited for siRNA delivery because 
CD7 is expressed by most T cells and 
is rapidly internalized. Moreover, this 
antibody has already been used in 
clinical studies to target toxins to T cell 
lymphomas and leukemias. In previous 
work, Kumar et al. (2007) demonstrated 
that the positively charged 9R peptide 
binds to polyanionic nucleic acids and 
can be used to deliver siRNA to neu-
ronal cells. They now show that these 
techniques can be used to suppress 
HIV-1 replication and prevent CD4+ T 
cell depletion in vivo in a humanized 
mouse model of acquired immune 
deficiency syndrome (AIDS). This is a 
significant advance, not only because 
these findings enhance the prospect 
of a new HIV-1/AIDS therapy but also 
because this study introduces an siRNA 
delivery system that could be adapted 
to target different receptors and hence 
other cell types. Moreover, given that 
the binding of the siRNA to the 9R tag 
is noncovalent, this approach should 
make it possible to easily compare the 
efficacy of different siRNAs.
The authors demonstrate that siRNAs 
protect immunodeficient mice trans-
planted with human peripheral blood 
leukocytes (the Hu-PBL mouse model) 
from challenge with cloned HIV-1. They 
also show that siRNAs can suppress 
virus replication in mice reconstituted 
with peripheral blood mononuclear cells 
derived from an HIV-1-infected individ-
ual. Thus, siRNAs may silence HIV-1 in 
vivo and can do so after the infection 
is already established. Of note, most T 
cells in the Hu-PBL model are activated 
by xenogeneic stimulation, thus mak-
ing it difficult to assess siRNA delivery 
to naive and resting T cells, which play 
an important role as viral reservoirs in 
HIV-infected humans. To address this 
issue, Kumar et al. engrafted newborn 
immunodeficient mice with human 
CD34+ hematopoietic stem cells. This 
model allows the generation of a com-
figure 1. silencing HIV-1 Infection in Humanized Mice
Immunodeficient mice (nonobese diabetic/severe combined immunodeficient interleukin-2 receptor γ 
knockout mice, NOD/SCIDIL2rγ−/−) engrafted with human peripheral blood mononuclear cells (PBMCs) or 
hematopoietic stem cells (HSCs) are injected with the CD7 antibody in complex with short interfering RNAs 
(scFvCD7-9R/siRNA). The siRNAs bind to the CD7 antibody through a polybasic peptide tag (nine arginines, 
9R) added to the antibody. This complex delivers the siRNAs into T cells by receptor-mediated endocytosis. 
Some siRNAs escape the endosomal compartment and associate with the RNA-induced silencing complex 
(RISC). Subsequently, one RNA strand is cleaved, and the remaining one guides the activated RISC complex 
to the complementary mRNA. As a result of this interaction, the mRNA is cleaved, and synthesis of the respec-
tive protein is disrupted. To inhibit HIV-1 infection, Kumar et al. (2008) used a combination of siRNAs targeting 
CCR5, the cellular coreceptor for HIV-1, and the viral proteins Tat and Vif. CCR5 is required for HIV-1 virion 
fusion, the transactivator Tat is needed for effective viral transcription, and Vif promotes infectivity by degrad-
ing the host factor APOBEC3G. If not degraded, APOBEC proteins are encapsidated into budding virions and 
cause hypermutation of the viral genome. Thus, this siRNA cocktail inhibits HIV-1 entry into the target cell, 
impairs the transcription of the proviral genome, and leads to the production of viral particles with reduced 
infectivity. Furthermore, siRNA treatment also leads to the degradation of genomic viral RNA.Cell 134, August 22, 2008 ©2008 Elsevier Inc. 567
plete hematopoietic system (Berges et 
al., 2006; Shultz et al., 2007) in which 
the majority of T cells show a resting 
phenotype. Remarkably, virus replica-
tion was markedly suppressed in these 
mice (chronically infected with HIV) after 
treatment with the siRNAs. Although 
the effects were less striking than 
those observed in the Hu-PBL mice, 
the improvement is notable considering 
that resting T cells are usually refractory 
to nucleic acid uptake.
Given that siRNAs usually reduce but 
do not entirely block protein expression, 
the observed levels of protection against 
HIV-1 infection are quite impressive. 
This was achieved with a combination 
of siRNAs targeting the cellular CCR5 
coreceptor and the viral proteins Tat 
and Vif. CCR5 is a chemokine receptor 
that is essential for the fusion between 
the viral and host cell membranes but 
can be silenced without toxicity. Tat is 
required for effective transcription of 
the proviral genome, whereas Vif medi-
ates the degradation of the cellular cyti-
dine deaminase APOBEC3G. If it is not 
degraded, APOBEC3G is incorporated 
into progeny virions, leading to lethal 
hypermutations in the viral genome 
upon infection of a new target cell. Thus, 
this combination siRNA therapy targets 
early, intermediate, and late steps of the 
virus life cycle. Similar to standard anti-
retroviral therapy, a combination of siR-
NAs appears to be essential to prevent 
the emergence of HIV-1 variants that 
escape treatment, because treatment 
with an siRNA targeting CCR5 alone 
was less effective than a combination of 
siRNAs in suppressing viral replication.
Notably, this study did not find evi-
dence of immunological toxicity, non-
specific immune activation, or altera-
tions in microRNA levels. Nevertheless, 
many parameters need to be optimized 
before this approach can be used in 
a clinical setting. For example, the 
efficiency of siRNA delivery must be 
improved, and additional antibodies 568 Cell 134, August 22, 2008 ©2008 Elsevneed to be developed to target mac-
rophages and dendritic cells that are 
also infected by HIV-1. A more difficult 
challenge will be to keep concentrations 
of siRNA within an effective range for 
several years during chronic HIV-1 infec-
tion, especially given that administration 
of siRNAs by intravenous injection every 
few days would be extremely expen-
sive and logistically arduous. Although 
improved delivery systems are currently 
being developed (Akhtar and Benter, 
2007) and chemical modifications may 
increase the stability, pharmacokinetics, 
and potency of siRNAs (Corey, 2007), 
additional technical breakthroughs are 
necessary before widespread clinical 
application would be possible. Vector-
mediated delivery of short hairpin RNAs 
(shRNAs) to hematopoietic stem cells 
is an alternative approach, but it has 
proven difficult to achieve and to main-
tain the expression of effective levels of 
shRNAs in vivo. Furthermore, it is very 
likely that HIV-1 escape variants will 
emerge during long-term treatment. 
This is not a crucial problem if one can 
rapidly switch to different siRNAs (as 
in the current study) but constitutes a 
major hurdle for approaches that rely on 
stable RNAi expression.
To date, more than 20 drugs against 
HIV/AIDS have been approved for clini-
cal use. Most of them are highly effec-
tive and can be administered orally. 
Because siRNA-based drugs are cur-
rently expensive and difficult to admin-
ister, it is unlikely that they will soon 
become a viable alternative to antiret-
roviral therapy or a treatment option for 
AIDS in developing countries. However, 
they may be useful for the treatment 
of individuals harboring HIV-1 variants 
resistant to existing drug regimens. 
Clearly, long-term silencing of a virus 
that is highly variable, infects various 
cell types, and persists for life is an 
extremely challenging task. However, 
there is also an urgent need for drugs 
against acute viral infections causing ier Inc.respiratory diseases, encephalitis, and 
hemorrhagic fever. The results of Kumar 
et al. show that the potency of silenc-
ing by siRNAs can be combined with 
the specificity of an antibody to deliver 
effective quantities of siRNAs into a 
specific cell type in vivo. In principle, 
antibodies could be directed against 
any surface protein and the addition of 
polybasic peptide tags to an antibody 
should allow the conjugation of any 
siRNA. It is this potential versatility that 
raises the hope that new siRNA-based 
drugs will one day be created to counter 
the numerous viral infections that cur-
rently cannot be treated.
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